iBio Inc.

AI Score

0

Unlock

2.70
-0.03 (-1.10%)
At close: Jan 15, 2025, 10:11 AM
undefined%
Bid 2.71
Market Cap 24.70M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.25
PE Ratio (ttm) -10.8
Forward PE n/a
Analyst Buy
Ask 2.74
Volume 19,092
Avg. Volume (20D) 109,957
Open 2.77
Previous Close 2.73
Day's Range 2.66 - 2.77
52-Week Range 1.02 - 4.98
Beta undefined

About IBIO

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing ...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 19, 2008
Employees 16
Stock Exchange AMEX
Ticker Symbol IBIO

Analyst Forecast

According to 3 analyst ratings, the average rating for IBIO stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 85.19% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
9 months ago · Source
+192.17%
IBio shares are trading higher after the company c... Unlock content with Pro Subscription